Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877389 | 0.83 | MAPK13 (0.38) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL3880327 | 0.82 | MAPK13 (0.38) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL5622448 | 0.80 | MAPK13 (0.38) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3884933 | 0.79 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL3884925 | 0.79 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL5622451 | 0.79 | MAPK13 (0.52) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3881036 | 0.78 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL3889121 | 0.78 | MAPK13 (0.61) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5622943 | 0.78 | MAPK13 (0.41) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL8273809 | 0.77 | MAPK13 (0.44) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482356-B2 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | claimed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | claimed |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | CLARK MICHAEL PHILIP | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | MAPK14 922/4885MAPK13 2033/4885MAPK12 2453/4885 |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | MAPK14 922/4885MAPK13 2033/4885MAPK12 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.